Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPureTech Regulatory News (PRTC)

Share Price Information for PureTech (PRTC)

Share Price is delayed by 15 minutes
Get Live Data
127.20    2.20 (1.76%)
Bid:
127.00
Ask:
127.60
Spread: 0.60 (0.472%)
Market Cap: £309.63m
PRTC Live PriceLast checked at - London Stock Exchange

Intraday PureTech Share Chart

Form 8.5 (EPT/RI)

10 Oct 2022 09:18

RNS Number : 3204C
Liberum Capital Limited
10 October 2022
 

 

FORM 8.5 (EPT/RI)

 

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

Liberum Capital Limited

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

PureTech Health plc

(c) Name of the party to the offer with which exempt principal trader is connected:

PureTech Health plc

(d) Date dealing undertaken:

07th October 2022

(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?

If it is a cash offer or possible cash offer, state "N/A"

No

 

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

Class of relevant security

Purchases/ sales

 

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

 

ORD 25p

 

 

Purchase

 

14,664

 

2.21

 

2.2

 

ORD 25p

 

 

Sale

 

14,664

 

2.21

 

2.2

 

 

(b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 

 

 

 

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

 

 

 

3. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

 

Date of disclosure:

10th October 2022

 

Contact name:

Kristina Kapur

Telephone number:

020 3100 2034

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service. 

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
FERGIBDGLBBDGDG
Date   Source Headline
24th Jun 20217:00 amRNSPDMR DEALING - PURCHASE OF SHARES
23rd Jun 20211:28 pmRNSKaruna Announces KarXT Results in Healthy Elderly
16th Jun 202112:00 pmRNSPureTech Acquires Alivio and Oral IL-22 Candidate
2nd Jun 20217:00 amRNSPDMR Notification RSU Vesting
1st Jun 20217:00 amRNSTotal Voting Rights
27th May 20216:16 pmRNSResult of AGM
27th May 20212:50 pmRNSPureTech’s Gelesis Presents Plenity Data at AACE
26th May 20211:05 pmRNSPureTech’s Akili Secures $160M in Financing
25th May 202112:00 pmRNSPRTC Presents at Jefferies Healthcare Conference
12th May 202112:00 pmRNSPureTech Forms IPF Clinical Advisory Board
28th Apr 20214:08 pmRNSNew PureTech Research Published in Nature Journal
26th Apr 20211:05 pmRNSGelesis Appoints Procter & Gamble Veteran to BOD
15th Apr 20217:00 amRNSFinal Results
12th Apr 202112:00 pmRNSPRTC Presents Data for LYT-210 IO Program at AACR
7th Apr 202112:00 pmRNSPureTech to Present at Two Investor Conferences
7th Apr 202110:15 amRNSAkili Collab to Study Long COVID-Related Brain Fog
26th Mar 202112:02 pmRNSAkili Data Published in Nature Digital Medicine
24th Mar 20217:00 amRNSHolding(s) in Company
18th Mar 20217:00 amRNSDirectorate Change
15th Mar 20217:00 amRNSNotice of Results
3rd Mar 202112:00 pmRNSPRTC Presents at Barclays Healthcare Conference
2nd Mar 20211:01 pmRNSKaruna Prices Approximately $250M Public Offering
25th Feb 20212:00 pmRNSPRTC Publishes Lymphatic Targeting Study for Glyph
25th Feb 20217:00 amRNSKaruna data in New England Journal of Medicine
18th Feb 202112:00 pmRNSPRTC Presents at SVB Leerink Healthcare Conference
10th Feb 20217:05 amRNSVor Closes Over $200M Initial Public Offering
10th Feb 20217:00 amRNSPRTC Receives $118M from Founded Entity Shares
8th Feb 202112:00 pmRNSVedanta Adds Biotech Finance and IR Expert as CFO
5th Feb 202111:46 amRNSPureTech Founded Entity Vor Lists on Nasdaq
5th Feb 20217:00 amRNSHolding(s) in Company
1st Feb 20217:00 amRNSTotal Voting Rights
29th Jan 20217:00 amRNSPureTech Appoints Bharatt Chowrira to BOD
18th Jan 20217:00 amRNSVor Files IPO Registration Statement on Nasdaq
14th Jan 202112:05 pmRNSVor Announces FDA Acceptance of IND Application
14th Jan 202111:50 amRNSAesthetic Med & Dermatology Veterans Join Follica
12th Jan 202111:50 amRNSVedanta Receives $25M Investment from Pfizer Inc
5th Jan 20217:00 amRNSPRTC Appoints Biotech Analyst & Senior Exec as CFO
4th Jan 20217:00 amRNSTotal Voting Rights
21st Dec 202012:00 pmRNSPureTech to Present at JPM and Other Conferences
21st Dec 20207:00 amRNSDirector/PDMR Shareholding
11th Dec 202012:00 pmRNSPRTC Starts LYT-200 Clinical Trial in Solid Tumors
11th Dec 20207:00 amRNSHolding(s) in Company
10th Dec 202012:00 pmRNSLYT-100 Advances to Phase 2a Study in Lymphedema
9th Dec 202012:00 pmRNSFollica Female Hair Loss Academic Study Published
3rd Dec 202012:00 pmRNSPureTech Initiates Ph 2 of LYT-100 in Long COVID
1st Dec 20207:00 amRNSTotal Voting Rights
30th Nov 202012:00 pmRNSPureTech to Host Virtual R&D Day for Investors
27th Nov 20204:41 pmRNSSecond Price Monitoring Extn
27th Nov 20204:37 pmRNSPrice Monitoring Extension
27th Nov 20207:05 amRNSPDMR DEALING - PURCHASE OF SHARES

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.